Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14159031 | 0.83 | HRH3 (0.51) | HRH3SIGMAR1 | |
| SCHEMBL13498014 | 0.81 | KDM4E (0.51) | HRH3KDM4E | |
| SCHEMBL11937213 | 0.81 | DRD2 (0.52) | HRH3ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL13439757 | 0.80 | P2RY1 (0.56) | HRH3P2RY1 | |
| SCHEMBL13439681 | 0.79 | MAOA (0.54) | — | |
| SCHEMBL20347959 | 0.78 | PARP15 (0.53) | HRH3ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL11937240 | 0.78 | PARP15 (0.53) | HRH3ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL13110224 | 0.76 | PARP15 (0.54) | HRH3ALDH1A1KDM4E | |
| SCHEMBL9347958 | 0.76 | SLC18A3 (0.46) | SIGMAR1 | |
| SCHEMBL13439722 | 0.74 | SLC6A5 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | HRH3 118/4885P2RY1 1/4885USP2 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.